Derivative exercise or conversion — not an open-market buy.
Transaction Mar 30, 2026 · Disclosed Jul 21, 2026
5 different filers disclosed JNJ within 90 days. Disclosed 113 days after the transaction; reported as an official range, not an exact amount.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
$1,001 - $15,000
Official band as filed. No midpoint or exact amount is implied
Filer
113 days
Days between the transaction date and the filing date
2 disclosures on this company by this filer
5 distinct filers within 90 days
Sits on the Senate Committee on Health, Education, Labor, and Pensions, whose remit includes drug, biotech and medical device makers.
Current committee assignments for the 119th Congress (unitedstates/congress-legislators, as of 2026-10-02). Which committees cover which sectors is OQRO's own editorial mapping, not an official classification. A committee seat is public information about a member's role, not a sign of what they knew or why they traded
Sponsored 1 bill in Health this Congress.
Bills (H.R. / S.) this member sponsored in the 119th Congress so far, including any introduced after the trade, grouped by the policy area the Congressional Research Service assigned (Congress.gov). Which policy areas relate to which sectors is OQRO's editorial mapping. Not a sign of what they knew or why they traded
Derivative exercise or conversion — not an open-market buy.
209K → 194K shares held−7% of their stake
Johnson & Johnson's WWC. Innovative Medicine sold $3.95M of Johnson & Johnson shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.